Navigation Links
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Date:12/6/2008

is not recommended and should be considered only with close medical supervision and under exceptional circumstances where the potential benefit outweighs the risk.

Because of the risk for hepatotoxicity and other risks, PROMACTA is available only through a restricted distribution program called PROMACTA CARES. Under the PROMACTA CARES Program, only prescribers, pharmacies, and patients registered with the program are able to prescribe, dispense, and receive PROMACTA. To enroll in the PROMACTA CARES Program, call 1-877-9-PROMACTA.

Warnings and Precautions:

Additional safety information regarding Risk of Hepatotoxicity: Reinitiating treatment with PROMACTA is not recommended. If the potential benefit for reinitiating PROMACTA treatment is considered to outweigh the risk for hepatotoxicity, then cautiously reintroduce PROMACTA and measure serum liver tests weekly during the dose adjustment phase. If liver test abnormalities persist, worsen or recur, then permanently discontinue PROMACTA. Exercise caution when administering PROMACTA to patients with hepatic disease. Use a lower starting dose of PROMACTA in patients with moderate to severe hepatic disease and monitor closely.

Bone Marrow Reticulin Formation and Risk for Bone Marrow Fibrosis: PROMACTA is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists increase the risk for development or progression of reticulin fibers within the bone marrow. Prior to initiation of PROMACTA, examine the peripheral blood smear closely to establish a baseline level of cellular morphologic abnormalities. Following identification of a stable dose of PROMACTA, perform CBC with WBC differential monthly. If the patient develops new or worsening morphological abnormalities or cytopenia(s), discontinue treatment with PROMACTA and consider a bone marrow biopsy, including staining for fibrosis.

Worsened Thrombocytopenia and Hemorrhage Risk
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
2. GEN Reports on the Trend Toward Predictive Toxicogenomics
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... MANALAPAN, N.J. , May 22, 2013 ... this opportunity to update shareholders about some recent company ... will expand its avenues of communication with shareholders. Integrating ... has launched a Facebook page and will post updates ... the Twitter hashtag is #medifirstusa. Says ...
(Date:5/22/2013)... May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the following conferences. ... Presentation date: Wednesday May 29, 2013 , Presentation time: ... Healthcare Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of ...
Breaking Medicine Technology:MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Medifirst Solutions, Inc. Announces Update To Shareholders 2Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today outlined its complete line ... of future products.  As a leading provider of diodes ... leverage its world-class manufacturing operations, technology expertise and packaging ...
... 18, 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... two upcoming investor conferences in Paris.  Dr. Fernandes will present ... a.m. CET, May 24, at the Hilton Arc de Triomphe. ... at 3:00 p.m. CET, May 24, at the Paris ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
(Date:5/22/2013)... Los Angeles, CA (PRWEB) May 22, 2013 ... board, The J. M. Smucker Company, and Danny ... Awards yesterday at the GS1 General Assembly and Global ... Mr. Smucker and Mr. Wegman were recognized for their ... Standards - the most broadly used supply chain standards ...
(Date:5/22/2013)... report these findings in the current online edition ... pan-European study could open up new possibilities of ... which tackle diseases before the patient,s nervous system ... group of genetic diseases of the cerebellum and ... have limited control of their muscles. They also ...
(Date:5/22/2013)... new guidelines the first in more than 35 ... for surgical patients. The recommendations, based on a lengthy ... (JHH), can potentially save the medical center more than ... , A report on the research that led up ... Anesthesiology , suggests millions of dollars a year ...
(Date:5/22/2013)... Toppik and Bosley hair fibers, two hair loss concealer products ... hair. Hair loss treatments can be a lengthy process. In ... waiting period, one can use these hair loss concealers. They ... surgery in general. , Bosley and Toppik Hair Thickening ... eliminate the appearance of balding and thinning hair. It is ...
(Date:5/22/2013)... NC (PRWEB) May 22, 2013 The 2013 ... (DSM-5) is the largest change to hit the field ... Jung Center is will help prepare for the release with ... therapists has been trained knowing no other diagnostic scheme besides ... DSM-5 diagnostic manual will be released worldwide. In honor of ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Johns Hopkins rewrites obsolete blood-ordering rules 2Health News:Johns Hopkins rewrites obsolete blood-ordering rules 3Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 2
... Conferring with pharmacists permits quicker changes in drugs, improved ... -- Monitoring your blood pressure at home and reporting ... keep blood pressure readings lower than standard care does, ... half of people who used this system of blood ...
... AUSTIN, TexasMechanical engineering Assistant Professor Adela Ben-Yakar at The ... "microscalpel" that destroys a single cell while leaving nearby ... for cancer, epilepsy and other diseases. , "You can ... damaging the cells above and below it," Ben-Yakar says. ...
... Brava, LLC announces a major milestone.,Since its introduction 7 ... have used the Brava Breast Enhancement System. The Brava,system ... from,Brava in the United States and through international distributors ... V. Freyre, President and CEO of Brava, "We are ...
... Cycle Would Create a ,Stampede, of Other ... WASHINGTON, June 24 As policymakers ... package, they face the decision of,either supporting ... postponing the Average Manufacturer Price (AMP) pharmacy ...
... WASHINGTON, June 24 The American Lung,Association commends ... its,passage of the Pulmonary and Cardiac Rehabilitation Act ... Patients and Providers Act of,2008, the Pulmonary and ... make life easier for millions of Americans who ...
... who goes for tests, study concludes , , TUESDAY, ... from colorectal cancer among minorities in United States may ... cultural barriers that lead to less preventative screening among ... The report, published in the June 23 issue of ...
Cached Medicine News:Health News:Going Online to Draw the Line on High Blood Pressure 2Health News:Going Online to Draw the Line on High Blood Pressure 3Health News:Laser surgery probe targets individual cancer cells 2Health News:Time for Policymakers to Choose: 'Prompt Pay' Mandate or Postpone AMP Reimbursement Cuts 2Health News:American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act 2Health News:Social, Health Care Factors Drive Colon Screen Disparities 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: